Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/breastcancer.1.003
EZH2 and cancer progression: An intricate relation that continues to grow
Kanchan Kumari1, Sandip K Mishra1,*
- 1Cancer Biology Laboratory, Department of Cancer Biology, Institute of Life Sciences (Department of Biotechnology) Bhubaneswar, Odisha, India
Corresponding Author
Sandip K Mishra, sandipkmishra@hotmail.com
Received Date: June 20, 2020
Accepted Date: August 07, 2020
Kumari K, Mishra SK. EZH2 and cancer progression: An intricate relation that continues to grow. J Breast Cancer Res 2020; 1(1):9-13.
Copyright: © 2020 Kumari K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are redited.
Recommended Articles
The role of MRI in detecting and characterizing brain metastases from breast cancer
Brain metastases are a feared complication of breast cancer, occurring in 15-25% of patients and being associated with poor prognosis and reduced quality of life. Magnetic resonance imaging (MRI) is an advanced technique that uses powerful magnetic fields and radio waves to produce detailed three-dimensional (3D) images of the brain's neuroanatomy and any potential pathology, especially in the management of brain metastases. The review article by Mohammadi et al. provides a timely and comprehensive overview of the utility of MRI for detecting and characterizing brain metastases from breast cancer.
Cryoablation is a safe alternative to surgery for low-risk breast cancer
Cryoablation of breast cancer offers an alternative to surgery for women who are not ideal surgical candidates. It is a minimally invasive procedure that has already had success in fibroadenoma treatment with good tumor reduction and cosmesis. The findings of cryoablation as treatment for early-stage, low-risk breast cancer has been previously discussed in the recently published article ‘Cryoablation: A promising non-operative therapy for low-risk breast cancer’.
DKK2 mediated immunosuppressive pathway and angiogenesis for colon cancer progression
Available targeted therapies for colorectal cancer (CRC) are limited. Immunotherapy offers new options for cancer treatment, but most of CRC are refractory to current immune checkpoint blockade, which indicates the possible presence of yet uncharacterized immune-suppressive mechanisms. Herein we report that high levels of Dickkopf-related protein 2 (DKK2) are expressed in human CRC tumors, and the DKK2 blockade caused stronger activation of tumor-infiltrating CD8+ T cells in ex vivo culture. A correlation of high DKK2 expression
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
Eight protein biomarkers (ER, PR, HER2, Cyclin A2, Cytokeratin 5, Vimentin, Bcl2, and Ki-67) were evaluated using tissue microarrays (TMAs) and immunohistochemistry (IHC). The IHC results from TMAs were analyzed by both supervised and unsupervised clustering methods. The predictive clusters for the supervised and unsupervised methods were compared for agreement with the empirical classification. Kappa values were used to determine the overall percent correct clusters and agreement between specific clusters.
EZH2 and cancer progression: An intricate relation that continues to grow
Genetic, epigenetic and environmental factors play disposing role in breast cancer initiation and progression. Oncogenes and tumor suppressor genes act as molecular players acting as activator, repressor or co-activator. Polycomb repressor protein Enhancer of Zeste Homolog 2 (EZH2) predominantly act as repressor protein have shown its substantial contribution in genetic, epigenetic as well as environmental factors induced breast tumor development.